Business
Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress
SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on supportive evidence regarding best approaches to managing tardive dyskinesia (TD) symptoms while maintaining control of the underlying psychiatric disorder. These results (abstract #29) will be shared at the MDS International Congress of Parkinson's Disease and Movement Disorders® September 15-18 in Madrid, Spain.\n\n \n \n \n \n \n \n\n \nThe case-based survey assessed practice, knowledge, and attitudes of psychiatrists and neurologists, including a subset of movement disorder specialists in the U.S., in managing of patients with TD across 3 timepoints (N=400 in May 2018, N=253 in March 2020, and N=202 in December 2021). Results demonstrate that:\nThe prevalence of TD continues to be underestimatedOver time, more respondents are considering pharmacologic therapy as initial management for patients with TD and opting for a VMAT2 inhibitor to manage TD movementsThe most common patient complaints prompting treatment for TD were patient embarrassment/social anxiety and effect on quality of lifeThe most significant perceived barrier to optimal management of TD continues to be apprehension of losing control of the patient's underlying psychiatric symptoms\"These survey findings demonstrate the continued importance of education for clinicians in the proactive screening, recognition, and treatment of TD as standard of care for at-risk populations,\" said Eiry W. Roberts, MD, Chief Medical Officer at Neurocrine Biosciences. \"Management of TD in conjunction with maintaining control of the underlying psychiatric disorder is of key importance. Neurocrine Biosciences is committed to furthering education on supportive evidence regarding pharmacologic approaches to the treatment of TD.\"\nA full list of abstracts being presented by Neurocrine Biosciences at MDS International Congress of Parkinson's Disease and Movement Disorders® is available on the meeting website.\nAbout Tardive Dyskinesia (TD)Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds ...